Skip to main content

Affymetrix and Decode Collaborate on Gene Tests for Common Diseases

NEW YORK, July 24 - Affymetrix and DeCode Genetics have signed an agreement to develop DNA-based tests for patient response to common disease treatments using Affymetrix GeneChip technology, the companies said Tuesday.

The companies willl conduct gene expression analysis on clinical trial populations to discover the genetic correlates for responses to drugs in diseases including high-cholesterol, depression, asthma, hypertension, breast cancer, schizophrenia and migraine. DeCode’s wholly-owned  pharmacogenomics subsidiary EnCode will conduct the clinical work in this collaboration. 

"By combining DeCode’s population resources for pharmacogenomics with Affymetrix' high-density GeneChip platform, we hope to expand the clinical use of gene expression profiles to predict drug response," Stephen Fodor, Affymetrix’ CEO, said in a statement. “We believe these studies will generate valuable new indicators of disease, thereby contributing to the development of more effective therapies."

Affymetrix and Decode, through Encode, will share any revenues from DNA-based tests the parties develop under the collaboration. The parties did not disclose further terms of the agreement.  
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.